文献速递心外重症与机械循环支持

有效直接抗病毒治疗时代使用丙型肝炎阳性供体进行心脏移植的早期结局

Early outcomes using hepatitis C-positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies.
PubMed 文献 · J Heart Lung Transplant · 2018-01-31

本研究报道了2016年9月至2017年3月单中心使用HCV阳性供体心脏为12例HCV初治患者和1例有治疗史患者行心脏移植的早期经验,9例术后出现HCV病毒血症,其中8例完成DAA治疗并获得治愈,1例治疗第7周死于肺栓塞,DAA耐受良好。

要点

  • HCV阳性供心移植后69%(9/13)受者出现病毒血症,8例完成DAA治疗均获治愈。
  • 1例受者在DAA治疗第7周死于肺栓塞。
  • 作者认为在高效DAA时代,使用HCV阳性供体是安全扩大供体池的潜在途径。

核心结论

  • 在高效直接抗病毒药物(DAA)时代,使用丙型肝炎病毒(HCV)阳性供体是安全扩大供体池的潜在途径,需额外随访以阐明长期结局。

研究设计与样本

  • 单中心前瞻性先导性研究,2016年9月至2017年3月纳入12例HCV初治患者和1例有治疗史患者,经知情同意后接受HCV阳性供体心脏移植,获得HCV感染者转诊肝病科并接受DAA治疗,数据收集与分析经机构审查委员会批准。

主要发现

  • 移植时受者平均年龄53±10岁,8例(61.5%)使用左心室辅助装置支持。
  • 同意考虑HCV阳性心脏后至移植的平均时间为11±12天。
  • 13例中9例(69%)移植后出现HCV病毒血症,其中8例完成DAA治疗并达到持续病毒学应答12周定义的治愈。
  • 1例在治疗第7周死于肺栓塞。
  • DAA在所有接受治疗的患者中耐受良好。

关键数值与推荐

  • 治愈定义为治疗结束后12周持续病毒学应答。

临床怎么用

  • 本研究中心的做法是经知情同意后为选定患者使用HCV阳性供体心脏,移植后出现HCV病毒血症者转诊肝病科并接受DAA治疗。

局限性

  • 原文指出需额外随访以阐明长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Given the shortage of suitable donor hearts for cardiac transplantation, and the favorable safety and efficacy of current agents used to treat hepatitis C virus (HCV), our institution recently piloted transplantation of select patients using HCV-positive donors. METHODS: Between September 2016 and March 2017, 12 HCV-naive patients and 1 patient with a history of treated HCV underwent heart transplantation (HT) using hearts from HCV-positive donors after informed consent. Patients who acquired HCV were referred to hepatology and treated with direct-acting anti-viral therapies (DAAs). Data collection and analysis were performed with institutional review board approval. RESULTS: At the time of HT, mean age of recipients was 53 ± 10 years, and 8 patients (61.5%) were on left ventricular assist device support. After consent to consider an HCV-positive heart, mean time to HT was 11 ± 12 days. Nine of 13 patients (69%) developed HCV viremia after transplant, including 8 who completed DAA treatment and demonstrated cure, as defined by a sustained virologic response 12 weeks after treatment. One patient died during Week 7 of his treatment due to pulmonary embolism. DAAs were well tolerated in all treated patients. CONCLUSIONS: In the era of highly effective DAAs, the use of HCV-positive donors represents a potential approach to safely expand the donor pool. Additional follow-up is needed to elucidate long-term outcomes.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Schlendorf KH, Zalawadiya S, Shah AS, et al. Early outcomes using hepatitis C-positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies. J Heart Lung Transplant. 2018. PMID: 29530322. doi:10.1016/j.healun.2018.01.1293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。